Literature DB >> 32032248

Primary Graft Failure but Treatment Success: A Case of Reversion to Heterozygosity After Allogeneic Hematopoietic Cell Transplantation With Autologous Hematopoietic Recovery in a Child With CBL-related Juvenile Myelomonocytic Leukemia.

Benjamin Oshrine1.   

Abstract

Juvenile myelomonocytic leukemia (JMML) typically requires allogeneic hematopoietic cell transplantation with full donor chimerism for cure. Certain genetic subtypes, including JMML due to germline mutations in CBL, can have a more indolent course. We describe a young male patient with CBL-related JMML who experienced primary graft failure after allogeneic hematopoietic cell transplantation. Despite autologous recovery, the resulting hematopoietic tissue did not harbor the original homozygous CBL mutations, due to reversion of prior loss of heterozygosity of the 11q chromosomal region. The patient remains disease free without further leukemia-directed therapy.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 32032248     DOI: 10.1097/MPH.0000000000001740

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  3 in total

Review 1.  Role of CBL Mutations in Cancer and Non-Malignant Phenotype.

Authors:  Davide Leardini; Daria Messelodi; Edoardo Muratore; Francesco Baccelli; Salvatore N Bertuccio; Laura Anselmi; Andrea Pession; Riccardo Masetti
Journal:  Cancers (Basel)       Date:  2022-02-08       Impact factor: 6.639

2.  Juvenile myelomonocytic leukemia in the molecular era: a clinician's guide to diagnosis, risk stratification, and treatment.

Authors:  Astrid Wintering; Christopher C Dvorak; Elliot Stieglitz; Mignon L Loh
Journal:  Blood Adv       Date:  2021-11-23

3.  Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia.

Authors:  Anna Hecht; Julia A Meyer; Astrid Behnert; Eric Wong; Farid Chehab; Adam Olshen; Aaron Hechmer; Catherine Aftandilian; Rukhmi Bhat; Sung Won Choi; Satheesh Chonat; Jason E Farrar; Mark Fluchel; Haydar Frangoul; Jennifer H Han; Edward A Kolb; Dennis J Kuo; Margaret L MacMillan; Luke Maese; Kelly W Maloney; Aru Narendran; Benjamin Oshrine; Kirk R Schultz; Maria L Sulis; David Van Mater; Sarah K Tasian; Wolf-Karsten Hofmann; Mignon L Loh; Elliot Stieglitz
Journal:  Haematologica       Date:  2022-01-01       Impact factor: 9.941

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.